In today’s briefing:
- Quiddity Leaderboard ASX Mar 25: Final Expectations; Momentum Still Intact
- Illumina Inc.: Is its Transition to NovaSeq X Series Noteworthy?
- Peptidream (4587 JP): 2024 Result Beats Guidance; Positive Outlook for 2025
- Mettler-Toledo: A Tale Of Geographic Expansion & Market Penetration To Sustain Its Growth Trajectory!
- Zimmer Biomet: The 6 Most Significant Forces Steering Its Performance into 2025 & Beyond!
- LH US – Labcorp Holdings: Is Its Stronghold in Diagnostics Under Threat?
Quiddity Leaderboard ASX Mar 25: Final Expectations; Momentum Still Intact
- In this insight, we take a look at the potential index changes for ASX 300, 200, 100, 50, and 20 in the run-up to the March 2025 index rebal event.
- We expect two changes for ASX 50, one change for ASX 100, and seven changes for ASX 200. Separately we see eight ADDs and six DELs for ASX 300.
- The official index changes will be announced after the close on Friday 7th March 2025.
Illumina Inc.: Is its Transition to NovaSeq X Series Noteworthy?
- Illumina, a leading genomic sequencing company, reported its financial results for the fourth quarter of 2024, marking a slight revenue increase of 1% year-over-year to $1.1 billion.
- This growth was primarily driven by high throughput sequencing consumables as the company continues to shift its customer base towards its new NovaSeq X series of instruments.
- The company placed 91 NovaSeq X instruments in the quarter, reaching an installed base of 630, and enjoyed a robust pull-through performance, averaging $1.3 million per system in 2024.
Peptidream (4587 JP): 2024 Result Beats Guidance; Positive Outlook for 2025
- Peptidream Inc (4587 JP) reported better-than-expected 2024 result, with all key parameters beating upwardly revised guidance. Both revenue and net profit hit record high.
- Larger than anticipated upfront associated with the expanded Novartis collaboration and increased milestone revenue contributed to the stellar performance of 2024.
- The company expects 2025 revenue to increase 5% YoY to ¥49B. Both core operating and operating profits are expected to increase 2% YoY and net profit by 1%.
Mettler-Toledo: A Tale Of Geographic Expansion & Market Penetration To Sustain Its Growth Trajectory!
- Mettler-Toledo International, Inc. recently concluded its fourth-quarter 2024 earnings call, where they reported a robust quarter, marked by solid financial performance and operational execution.
- The company noted strong customer demand for its Laboratory products, particularly in Europe, which, alongside effective margin improvement initiatives, resulted in commendable adjusted EPS and cash flow.
- Despite challenging market conditions, Mettler-Toledo succeeded in delivering positive financial outcomes and continues to focus on long-term growth strategies like innovation and market leadership extension.
Zimmer Biomet: The 6 Most Significant Forces Steering Its Performance into 2025 & Beyond!
- Zimmer Biomet reported its fourth-quarter and full-year 2024 financial results, reflecting a complex but strategically advancing fiscal year.
- The company achieved a constant currency revenue growth of nearly 5%, marking its twelfth consecutive quarter of at least mid-single-digit growth.
- This robust performance, despite challenges like ERP implementation setbacks, underscores Zimmer Biomet’s resilience amidst a volatile market landscape.
LH US – Labcorp Holdings: Is Its Stronghold in Diagnostics Under Threat?
- Laboratory Corporation of America Holdings (LabCorp) presented a mixed but generally positive financial report in their latest call, providing signals for investors to weigh both an optimistic outlook and some ongoing challenges.
- LabCorp’s performance in 2024 was highlighted by a 10% increase in revenue compared to the previous year, totaling $3.3 billion for the fourth quarter alone.
- Their Diagnostics and Biopharma Laboratory Services segments each demonstrated a commendable 10% growth.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
